surgumedВестник СурГУ. МедицинаVestnik SurGU. Meditsina2949-3447Сургутский государственный университет10.1234/10.34822/2304-9448-2022-3-8-13surgumed-550Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНА. ОБЗОР ЛИТЕРАТУРЫCLINICAL MEDICINE. REVIEWSОСОБЕННОСТИ ПОЧЕЧНОГО ПОВРЕЖДЕНИЯ У КОМОРБИДНЫХ БОЛЬНЫХ В ПЕРИОД ПАНДЕМИИ КОРОНАВИРУСНОЙ ИНФЕКЦИИFEATURES OF KIDNEY INJURY IN PATIENTS WITH COMORBIDITIES DURING CORONAVIRUS PANDEMIChttps://orcid.org/0000-0003-1580-5162СундуковаЕ. А.SundukovaE. A.

врач-нефролог высшей категории

E-mail: Dr.Sundukova@yandex.ru

Highest Category Nephrologist

E-mail: Dr.Sundukova@yandex.ru

https://orcid.org/0000-0002-0149-6103АрямкинаО. А.AryamkinаO. L.

доктор медицинских наук, профессор

E-mail: arjam56@mail.ru

Doctor of Sciences (Medicine), Professor

E-mail: arjam56@mail.ru

Сургутский государственный университет, Сургут; Центральная больница Малоярославецкого района, МалоярославецРоссияSurgut State University, Surgut; Maloyaroslavets Central HospitalRussian FederationСургутский государственный университетРоссияSurgut State University, SurgutRussian Federation20222109202203 (53)813Copyright © Сундукова Е.А., Арямкина О.А., 20222022Сундукова Е.А., Арямкина О.А.Sundukova E.A., Aryamkinа O.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.surgumed.ru/jour/article/view/550

Цель – оценить особенности почечного повреждения у коморбидных больных с коронавирусной инфекцией. Материалы и методы. Проведен обзор данных научной литературы по вопросам патогенеза, течения, исходов и прогноза СOVID-19, в том числе обзоры рандомизированных контролируемых клинических исследований. Результаты. COVID-19 – это тяжелое заболевание, усугубляющее или вызывающее de novo патологию почек. Почки – таргетный орган для новой инфекции. Коморбидные пациенты являются группой высокого риска неблагоприятного исхода COVID-19.

The study aims to evaluate characteristics of kidney injury in COVID-19 patients with comorbidities. Materials and methods. Literature on the topic of pathogenesis, course, outcome, and prognosis of COVID-19 as well as randomized controlled clinical trials were reviewed. Results. COVID-19 is a severe disease that can worsen or cause kidney injury de novo. Kidney is the primary target organ for novel infection. Patients with comorbidities are also at higher risk for adverse COVID-19 outcomes.

Ковид-19патогенезпатология почеккоморбидностьCOVID-19pathogenesiskidney injurycomorbidityReferencesБолевич С. Б., Болевич С. С. Комплексный механизм развитияБолевич С. Б., Болевич С. С. Комплексный механизм развитияСOVID-19 // Сеченовский вестник. 2020. Т. 11, № 2. С. 50–61.СOVID-19 // Сеченовский вестник. 2020. Т. 11, № 2. С. 50–61.Wan Y., Shang J., Graham R., Baric R. S., Li F. Receptor Recognition byWan Y., Shang J., Graham R., Baric R. S., Li F. Receptor Recognition bythe Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus // J Virol. 2020. Vol. 94, № 7. P. e00127-20.the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus // J Virol. 2020. Vol. 94, № 7. P. e00127-20.Qi F., Qiang S., Zhang S., Zhang Z. Single Cell RNA Sequencing of 13 Human Tissues Identify Cell Types and Receptors of Human Coronaviruses // Biochem Biophys Res Comm. 2020. Vol. 526, Is. 1. P. 135–140.Qi F., Qiang S., Zhang S., Zhang Z. Single Cell RNA Sequencing of 13 Human Tissues Identify Cell Types and Receptors of Human Coronaviruses // Biochem Biophys Res Comm. 2020. Vol. 526, Is. 1. P. 135–140.Batlle D., Soler M. J., Sparks M. A. et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology // J Am Soc Nephrol. 2020. Vol. 31, Is. 7. P. 1380–1383.Batlle D., Soler M. J., Sparks M. A. et al. Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology // J Am Soc Nephrol. 2020. Vol. 31, Is. 7. P. 1380–1383.Томилина Н. А. Covid-19: связь с патологией почек: обзор литературы // Нефрология и диализ. 2021. Т. 23, № 2. С. 147–159.Томилина Н. А. Covid-19: связь с патологией почек: обзор литературы // Нефрология и диализ. 2021. Т. 23, № 2. С. 147–159.Wang D., Hu B., Hu C. et al. Clinical Characteristics of 138 HospitalizedWang D., Hu B., Hu C. et al. Clinical Characteristics of 138 HospitalizedPatients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China // JAMA. 2020. Vol. 323, Is. 11. P. 1061–1069.Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China // JAMA. 2020. Vol. 323, Is. 11. P. 1061–1069.Арутюнов Г. П. и др. Международный регистр «Анализ динамикиАрутюнов Г. П. и др. Международный регистр «Анализ динамикиКоморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2» (АКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции // Российский кардиологический журнал. 2021. Т. 26, № 4. С. 4470.Коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2» (АКТИВ SARS-CoV-2): анализ предикторов неблагоприятных исходов острой стадии новой коронавирусной инфекции // Российский кардиологический журнал. 2021. Т. 26, № 4. С. 4470.Столяревич Е. С. Поражение почек при COVID-19: клинические и морфологические проявления почечной патологии у 220 пациентов, умерших от COVID-19 // Нефрология и диализ. 2020. Т. 22. Спецвып. С. 46–55.Столяревич Е. С. Поражение почек при COVID-19: клинические и морфологические проявления почечной патологии у 220 пациентов, умерших от COVID-19 // Нефрология и диализ. 2020. Т. 22. Спецвып. С. 46–55.Зайратьянц О. В. и др. Патологическая анатомия COVID-19: опытЗайратьянц О. В. и др. Патологическая анатомия COVID-19: опытаутопсий // Судебная медицина. 2020. Т. 6, № 4. С. 10–23.аутопсий // Судебная медицина. 2020. Т. 6, № 4. С. 10–23.Zou X., Chen K., Zoou J. et al. Single-Cell RNA-seq Data Analysis onZou X., Chen K., Zoou J. et al. Single-Cell RNA-seq Data Analysis onthe Receptor ACE2 Expression Reveals the Potential Risk of Different Human Organs Vulnerable to 2019-nCoV Infection // Front Med. 2020. Vol. 14, Is. 2. P. 185–192.the Receptor ACE2 Expression Reveals the Potential Risk of Different Human Organs Vulnerable to 2019-nCoV Infection // Front Med. 2020. Vol. 14, Is. 2. P. 185–192.Gagliardi I., Patella G., Michael A. et al. COVID-19 and the Kidney: From Epidemiology to Clinical Practice // J Clin Med. 2020. Vol. 9, Is. 8. P. 2506.Gagliardi I., Patella G., Michael A. et al. COVID-19 and the Kidney: From Epidemiology to Clinical Practice // J Clin Med. 2020. Vol. 9, Is. 8. P. 2506.Cohen J. B., South A. M., Shaltout H. A., Sinclair M. R., Sparks M. A. etCohen J. B., South A. M., Shaltout H. A., Sinclair M. R., Sparks M. A. etal. Renin–Angiotensin System Blockade in the COVID-19 Pandemic // Clin Kidney J. 2021. Vol. 14, Is. Supplement_1. P. i48–i59.al. Renin–Angiotensin System Blockade in the COVID-19 Pandemic // Clin Kidney J. 2021. Vol. 14, Is. Supplement_1. P. i48–i59.Xiao L., Sakagami H., Miwa N. ACE2: The Key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? // Viruses. 2020. Vol. 12, Is. 5. P. 491.Xiao L., Sakagami H., Miwa N. ACE2: The Key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel? // Viruses. 2020. Vol. 12, Is. 5. P. 491.Li X., Geng M., Peng Y., Meng L., Lu S. Molecular Immune Pathogenesis and Diagnosis of COVID-19 // J Pharm Anal. 2020. Vol. 10, Is. 2. P. 102–108.Li X., Geng M., Peng Y., Meng L., Lu S. Molecular Immune Pathogenesis and Diagnosis of COVID-19 // J Pharm Anal. 2020. Vol. 10, Is. 2. P. 102–108.Engelmann B., Massberg S. Thrombosis as an Intravascular EffectorEngelmann B., Massberg S. Thrombosis as an Intravascular Effectorof Innate Immunity // Nat Rev Immunol. 2013. Vol. 13, Is. 1. P. 34–45.of Innate Immunity // Nat Rev Immunol. 2013. Vol. 13, Is. 1. P. 34–45.Jayarangaiah A., Kariyanna P. T., Chen X., Jayarangaiah A., Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response // Clin Appl Thromb Hemost. 2020. Vol. 26. DOI 10.1177/1076029620943293.Jayarangaiah A., Kariyanna P. T., Chen X., Jayarangaiah A., Kumar A. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response // Clin Appl Thromb Hemost. 2020. Vol. 26. DOI 10.1177/1076029620943293.Tang N., Li D., Wang X., Sun Z. Abnormal Coagulation Parameters AreTang N., Li D., Wang X., Sun Z. Abnormal Coagulation Parameters AreAssociated with Poor Prognosis in Patients with Novel CoronavirusAssociated with Poor Prognosis in Patients with Novel CoronavirusPneumonia // J Thromb Haemost. 2020. Vol. 18, Is. 5. P. 844–847.Pneumonia // J Thromb Haemost. 2020. Vol. 18, Is. 5. P. 844–847.Su H., Yang M, Wan C. et al. Renal Histopathological Analysis of 26Su H., Yang M, Wan C. et al. Renal Histopathological Analysis of 26Postmortem Findings of Patients with COVID-19 in China // KidneyPostmortem Findings of Patients with COVID-19 in China // KidneyInt. 2020. Vol. 98, Is. 1. P. 219–227.Int. 2020. Vol. 98, Is. 1. P. 219–227.Hoilat G. J., Das G., Shahnawaz M., Shanley P., Bukhari S. H. COVID-19Hoilat G. J., Das G., Shahnawaz M., Shanley P., Bukhari S. H. COVID-19Induced Collapsing Glomerulopathy and Role of APOL1 // QJM. 2020. Vol. 114, Is. 4. P. 263–264.Induced Collapsing Glomerulopathy and Role of APOL1 // QJM. 2020. Vol. 114, Is. 4. P. 263–264.Kissling S., Rotman S., Gerber C. et al. Collapsing Glomerulopathy inKissling S., Rotman S., Gerber C. et al. Collapsing Glomerulopathy ina COVID-19 Patient // Kidney Int. 2020. Vol. 98, Is. 1. P. 228–231.a COVID-19 Patient // Kidney Int. 2020. Vol. 98, Is. 1. P. 228–231.Narayanan M. The Many Faces of Infection in CKD: Evolving Paradigms, Insights, and Novel Therapies // Adv Chronic Kidney Dis. 2019. Vol. 26, Is. 1. P. 5–7.Narayanan M. The Many Faces of Infection in CKD: Evolving Paradigms, Insights, and Novel Therapies // Adv Chronic Kidney Dis. 2019. Vol. 26, Is. 1. P. 5–7.Cheng Y., Luo R., Wang K. et al. Kidney Disease Is Associated with In-Hospital Death of Patients with COVID-19 // Kidney Int. 2020. Vol. 97, Is. 5. P. 829–838.Cheng Y., Luo R., Wang K. et al. Kidney Disease Is Associated with In-Hospital Death of Patients with COVID-19 // Kidney Int. 2020. Vol. 97, Is. 5. P. 829–838.The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT)The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT)Working Group. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-Analysis // JAMA. 2020. Vol. 324, Is. 13. P. 1330–1341.Working Group. Association between Administration of Systemic Corticosteroids and Mortality among Critically Ill Patients with COVID-19: A Meta-Analysis // JAMA. 2020. Vol. 324, Is. 13. P. 1330–1341.Wu J., Li J., Zhu G. et al. Clinical Features of Maintenance Hemodialysis Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China // Clin J Am Soc Nephrol. 2020. Vol. 15, Is. 8. P. 1139–1145.Wu J., Li J., Zhu G. et al. Clinical Features of Maintenance Hemodialysis Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China // Clin J Am Soc Nephrol. 2020. Vol. 15, Is. 8. P. 1139–1145.Nuzzo D., Picone P. Potential Neurological Effects of Severe COVID-19 Infection // Neurosci Res. 2020. Vol. 158. P. 1–5.Nuzzo D., Picone P. Potential Neurological Effects of Severe COVID-19 Infection // Neurosci Res. 2020. Vol. 158. P. 1–5.Зубкин М. Л. и др. Новая коронавирусная инфекция и гемодиализ: течение и предикторы неблагоприятного исхода // Нефрология и диализ. 2021. Т. 23, № 4. С. 489–498.Зубкин М. Л. и др. Новая коронавирусная инфекция и гемодиализ: течение и предикторы неблагоприятного исхода // Нефрология и диализ. 2021. Т. 23, № 4. С. 489–498.Edler C., Schroder A. S., Aepfelbacher M. et al. Dying with SARSCoV-Edler C., Schroder A. S., Aepfelbacher M. et al. Dying with SARSCoV-Infection – An Autopsy Study of the First Consecutive 80 Cases in Hamburg, Germany // International Journal of Legal Medicine. 2020. Vol. 134, Is. 4. P. 1275–1284.Infection – An Autopsy Study of the First Consecutive 80 Cases in Hamburg, Germany // International Journal of Legal Medicine. 2020. Vol. 134, Is. 4. P. 1275–1284.Barron E., Bakhai C., Kar P. et al. Associations of Type 1 and Type 2Barron E., Bakhai C., Kar P. et al. Associations of Type 1 and Type 2Diabetes with COVID-19-Related Mortality in England: A Whole-Population Study // Lancet Diabetes Endocrinol. 2020. Vol. 8, Is. 10. P. 813–822.Diabetes with COVID-19-Related Mortality in England: A Whole-Population Study // Lancet Diabetes Endocrinol. 2020. Vol. 8, Is. 10. P. 813–822.Cheng S., Zhao Y., Wang F. et al. Comorbidities’ Potential Impacts on Severe and Non-Severe Patients with COVID-19: A Systematic Review and Meta-Analysis // Medicine (Baltimore). 2021. Vol. 100, Is. 12. P. E24971.Cheng S., Zhao Y., Wang F. et al. Comorbidities’ Potential Impacts on Severe and Non-Severe Patients with COVID-19: A Systematic Review and Meta-Analysis // Medicine (Baltimore). 2021. Vol. 100, Is. 12. P. E24971.Onder G. et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy // J Am Med Assoc. 2020. Vol. 323, № 18. P. 1775–1776.Onder G. et al. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy // J Am Med Assoc. 2020. Vol. 323, № 18. P. 1775–1776.Pati S., Mahapatra P., Kanungo S., Uddin A., Sahoo K. C. ManagingPati S., Mahapatra P., Kanungo S., Uddin A., Sahoo K. C. ManagingMultimorbidity (Multiple Chronic Diseases) Amid COVID-19 Pandemic: A Community Based Study from Odisha, India // Front Public Health. 2021. Vol. 8. P. 584408.Multimorbidity (Multiple Chronic Diseases) Amid COVID-19 Pandemic: A Community Based Study from Odisha, India // Front Public Health. 2021. Vol. 8. P. 584408.Nanda S., Toussaint L., Vincent A. et al. A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 // J Prim Care Community Health. 2021. Vol. 12. DOI 10.1177/21501327211010991.Nanda S., Toussaint L., Vincent A. et al. A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19 // J Prim Care Community Health. 2021. Vol. 12. DOI 10.1177/21501327211010991.

The authors declare that there are no conflicts of interest present.